SERPINF1

(redirected from PEDF)
Also found in: Acronyms.

SERPINF1

A gene on chromosome 17p13.3 that encodes a member of the serine protease inhibitor (serpin) family. SERPINF1 does not undergo the S (stressed) to R (relaxed) conformational transition characteristic of active serpins; it has no serine protease inhibitory activity, but it inhibits angiogenesis and is a neurotrophic factor involved in neuronal differentiation in retinoblastoma cells.
Mentioned in ?
References in periodicals archive ?
Second, PEDF challenged legislation that appropriated up to $50 million in royalty money to DCNR (subject to the availability of funds) and required DCNR to prioritize expenditure of those funds for state forests and parks.
Blood was drawn from the antecubital vein in the morning to determine PEDF and blood chemistries.
The company combines its patented gene transfer technologies with proprietary the>rapeutic genes to create product candidates, such as BIOBYPASS angiogen and GENSTENT biologic that address medical needs in the areas of cardiovascular disease, TNFerade biologic for oncology and the PEDF program for ophthalmology.
For many, the primary one is a lack of financial management skills, so PEDF helps them create a simple accounting system.
Our research was able to show that increasing PEDF not only causes Type 2 diabetes like complications but that blocking PEDF reverses these effects.
Each of our gene-based product candidates uses a common patent- protected technology platform to deliver genes that produce medically beneficial proteins directly at the site of disease -- TNFerade(TM) for oncology, BIOBYPASS(R) for cardiovascular disease, and PEDF for ophthalmology.
GenVec recently reported encouraging results from a Phase 1 dose- escalation study testing its gene-based PEDF product candidate in patients with advanced wet age-related macular degeneration (AMD).
This license expands the portfolio of patents previously licensed by GenVec, which already includes the PEDF gene, and covers broad composition of matter rights and related methods of use.
Our studies reported today demonstrated delivery of PEDF, a potent factor capable of both blocking and reversing animal models of AMD.
We are preparing to initiate the randomized, controlled NOVA trial (NOGA Delivery of VEGF for Angina) to test BIOBYPASS(R) in 'no-option' patients with severe coronary artery disease, expanding testing of our PEDF (Pigment Epithelium-Derived Factor) candidate in patients with wet age-related macular degeneration, and working to resolve the clinical hold on our cancer drug candidate, TNFerade(TM).
Previous animal studies have shown the potential benefits of increasing PEDF expression in the eye to prevent the growth of blood vessels (angiogenesis) that leads to vision loss.